These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 28275958)

  • 1. Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
    Kay S; Strickson A; Puelles J; Selby R; Benson E; Tolley K
    Diabetes Ther; 2017 Apr; 8(2):251-273. PubMed ID: 28275958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison.
    Craddy P; Palin HJ; Johnson KI
    Diabetes Ther; 2014 Jun; 5(1):1-41. PubMed ID: 24664619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
    Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
    PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus.
    Gordon J; McEwan P; Hurst M; Puelles J
    Diabetes Ther; 2016 Dec; 7(4):825-845. PubMed ID: 27787778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
    Lin WQ; Cai ZJ; Chen T; Liu MB; Li N; Zheng B
    Front Endocrinol (Lausanne); 2021; 12():684960. PubMed ID: 34484112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alogliptin: a new addition to the class of DPP-4 inhibitors.
    Andukuri R; Drincic A; Rendell M
    Diabetes Metab Syndr Obes; 2009 Jul; 2():117-26. PubMed ID: 21437125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
    Foroutan N; Muratov S; Levine M
    Clin Invest Med; 2016 Apr; 39(2):E48-62. PubMed ID: 27040861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
    Lorenzi M; Ploug UJ; Langer J; Skovgaard R; Zoratti M; Jansen J
    Diabetes Ther; 2017 Feb; 8(1):85-99. PubMed ID: 27995594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis.
    Lautsch D; Alsumali A; McLeod E; Kuang Y; He J; Singh R; Nevo A; Arnet U; Uyei J; Rajpathak S
    Diabetes Ther; 2021 Jan; 12(1):389-418. PubMed ID: 33313996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting.
    Strain WD; McEwan P; Howitt H; Meadowcroft S
    Diabetes Ther; 2019 Aug; 10(4):1499-1507. PubMed ID: 31264097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
    Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
    Richard KR; Shelburne JS; Kirk JK
    Clin Ther; 2011 Nov; 33(11):1609-29. PubMed ID: 22071236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
    Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
    J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.